Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey - 2Belarusian parliament passes a bill to crack down on LGBTQ+ rights
- 3Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- 4Best Wellness Tracker Keep You On target
- 53 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- UN rights chief says Israeli policy in West Bank 'resembles apartheid system'
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- San Francisco mayor says city in talks to bring pandas back to zoo ahead of trip to Asia
- The 12 biggest space stories of 2025 — according to you
- Becoming the best at Discussion: Individual Procedures
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- NASA's Voyager 1 set to achieve historic distance from Earth
- Vote in favor of your favored spot to peruse
